All posts by biorab

04Jan/18

FDA approves emicizumab-kxwh for prevention and reduction of bleeding in patients with hemophilia A with factor VIII inhibitors

“Emicizumab (trade name Hemlibra, emicizumab–kxwh, ACE910, RO5534262) is a bispecific IgG4 mAb targeting Factors IXa and X. On November 16, 2017, the drug (emicizumab–kxwh) was approved by Food and Drug Administration (FDA) approved to preventRead More…